| Literature DB >> 8985191 |
M E Boursnell1, C Entwisle, D Blakeley, C Roberts, I A Duncan, S E Chisholm, G M Martin, R Jennings, D Ni Challanaín, I Sobek, S C Inglis, C S McLean.
Abstract
A glycoprotein H (gH)-deleted herpes simplex virus type 2 (HSV-2) was evaluated as a vaccine for the prevention of HSV-induced disease. This virus, which we term a DISC (disabled infectious single cycle) virus, can only complete one replication cycle in normal cells and should thus be safe yet still able to stimulate broad humoral and cell-mediated antiviral immune responses. A gH-deleted HSV-2 virus that has been tested as a vaccine in the guinea pig model of recurrent HSV-2 infection was constructed. Animals vaccinated with DISC HSV-2 showed complete protection against primary HSV-2-induced disease, even when challenged 6 months after vaccination. In addition, the animals were almost completely protected against recurrent disease. Even at low vaccination doses, there was a high degree of protection against primary disease. A reduction in recurrent disease symptoms was also observed following therapeutic vaccination of animals already infected with wild type HSV-2.Entities:
Mesh：
Substances：
Year: 1997 PMID： 8985191 PMCID： PMC7109964 DOI： 10.1093/infdis/175.1.16
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226